Monday, October 06, 2025 8:16:29 PM
For SGMO to be compliant with the deficiency notice by Oct 23, it means they would need to start trading at $1 or above for ten consecutive trading days before the initial deadline of Oct 23 (which is Oct 9th). For example, if on Oct 10, nine trading days before the deadline, they started trading at or above $1, and stayed there thru Oct 23, they would be considered non-compliant. They would need to ask for an extension, and if granted, they would be given another 180 days to become compliant. They can't ''bank'' the nine consecutive days of trading above $1. Meaning, the first compliance period is over, and a new 180 day compliance period starts with a ''new'' ten trading day trading above $1 requirement to meet compliance.
But in all likelihood they would be granted the new extension. But if Oct 23rd come around and the company is not trading above $1 it's likely because they have bigger problems. Point is they are weeks from insolvency at this point. Something has to happen...!
But in all likelihood they would be granted the new extension. But if Oct 23rd come around and the company is not trading above $1 it's likely because they have bigger problems. Point is they are weeks from insolvency at this point. Something has to happen...!
Recent SGMO News
- Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/14/2026 08:01:00 PM
- Sangamo Therapeutics Announces First Quarter 2026 Earnings Call • GlobeNewswire Inc. • 05/11/2026 08:05:00 PM
- Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) • GlobeNewswire Inc. • 04/30/2026 12:05:00 PM
- Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market • IH Market News • 04/29/2026 02:45:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:37:29 PM
- Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market • GlobeNewswire Inc. • 04/29/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:07:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/23/2026 08:05:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:01:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:35:30 PM
